|
EMEA Provides Guidance on Chronic Hepatitis C Trials
The primary endpoint for confirmatory efficacy studies of treatments for chronic hepatitis C (CHC) should be sustained virological response (SVR), according to a draft guideline from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives